NYSE$TDOC
Teladoc Health Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Teladoc Health's third quarter results reflected revenue growth and adjusted EBITDA exceeding expectations.
Teladoc Health reported a 17% increase in revenue, reaching $611.4 million. The net loss was $73.5 million, or $0.45 per share. Adjusted EBITDA totaled $51.2 million. Cash flow from operating activities was $63.0 million for the quarter.
- Third quarter revenue grew 17% year-over-year to $611.4 million.
- Net loss totaled $73.5 million, or $0.45 per share.
- Adjusted EBITDA totaled $51.2 million.
- Cash flow from operating activities was $63.0 million for the quarter.
Headline financials
Revenue & EPS history
Teladoc · Revenue · Quarterly
$611M
Revenue by segment
Teladoc · $660M total across 2 segments · Q3 2023
- Integrated Care$374M—56.7%
- BetterHelp$286M—43.3%
Forward guidance
Teladoc Health provided its outlook for the fourth quarter and full year 2022, based on current market conditions and expectations.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-1.2%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
49%
21 / 43 earnings
Positive
+23.7%
Q2 2023
Best reaction
-42.0%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +1.8% | +11.9% | +27.9% | |
| Q4 2025 | +15.5% | +9.7% | +10.5% | |
| Q3 2025 | +6.2% | -3.0% | -7.8% | |
| Q1 2025 | -2.8% | -5.7% | -3.8% | |
| Q4 2024 | -13.6% | -16.3% | -26.4% | |
| Q3 2024 | +0.9% | -0.6% | +34.3% | |
| Q2 2024 | -11.7% | -21.9% | -26.3% | |
| Q1 2024 | -5.2% | -7.1% | -16.4% | |
| Q4 2023 | -25.6% | -31.1% | -27.3% | |
| Q3 2023 | -3.3% | -13.5% | -5.3% | |
| Q2 2023 | +23.7% | +20.9% | -6.1% | |
| Q1 2023 | +3.4% | +2.2% | -14.4% | |
| Q4 2022 | -3.9% | -5.4% | -12.2% | |
| Q3 2022 | +6.4% | +10.8% | +3.2% | |
| Q2 2022 | -11.4% | -8.4% | -20.1% | |
| Q1 2022 | -42.0% | -35.7% | -38.1% | |
| Q4 2021 | -5.4% | +8.8% | +6.8% | |
| Q3 2021 | +5.6% | +7.2% | -22.4% | |
| Q2 2021 | +1.4% | -0.9% | -5.5% | |
| Q1 2021 | -10.1% | -14.1% | -20.7% | |
| Q4 2020 | -14.2% | -12.7% | -30.9% | |
| Q3 2020 | -2.3% | -14.6% | -11.9% | |
| Q2 2020 | +11.5% | +11.5% | -1.9% | |
| Q1 2020 | -9.1% | -3.8% | -3.9% | |
| Q4 2019 | +14.1% | +5.1% | +38.6% | |
| Q3 2019 | +7.1% | +12.3% | +17.1% | |
| Q2 2019 | +1.9% | -6.5% | -17.5% | |
| Q1 2019 | -2.0% | +2.9% | -1.8% | |
| Q4 2018 | -4.5% | -6.3% | -17.5% | |
| Q3 2018 | +4.6% | -8.6% | -9.9% | |
| Q2 2018 | +9.0% | +10.3% | +29.6% | |
| Q1 2018 | +5.7% | -1.9% | +18.4% | |
| Q4 2017 | +4.0% | +8.8% | +4.5% | |
| Q3 2017 | -3.0% | -5.4% | +8.0% | |
| Q2 2017 | -7.1% | -2.6% | +5.5% | |
| Q1 2017 | +23.3% | +26.9% | +46.3% | |
| Q4 2016 | +6.8% | -4.8% | +13.4% | |
| Q3 2016 | +6.2% | +8.6% | +19.4% | |
| Q2 2016 | -16.1% | -9.0% | +2.9% | |
| Q1 2016 | -1.5% | — | — | |
| Q4 2015 | -7.3% | — | — | |
| Q3 2015 | -10.6% | — | — | |
| Q2 2015 | +3.6% | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro